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responsibilities and rights
Based on recent reports,1-9 there are increasing con-
cerns about the control of the scientific data obtained from
clinical trials sponsored by industry. Many of the problems
encountered are the result of restrictions contained in the
research contracts that participating investigators are asked
to sign. A number of solutions have been suggested to
ensure the integrity of clinical trials, including the establish-
ment of appropriately constituted trial oversight commit-
tees, negotiating noninterference pledges from industry
sponsors, and creating proactive support of investigators’
rights by organized medicine.10 As surgical journal editors,
we stand opposed to inappropriately restrictive contractual
agreements governing company-sponsored clinical trials of
devices or drugs, such as those containing clauses that deny
the investigators proper control over the scientific aspects
of the trial or restrict access to the data and their timely
publication. We believe that responsibility for the scientific
data from clinical trials and its analysis, interpretation, and
publication should rest in the hands of the investigators. In
multicenter trials, a duly appointed and properly consti-
tuted publications committee can and usually should carry
out these responsibilities.
Recently, the editors of 13 medical journals also pub-
lished their opposition to inappropriately restrictive re-
search contracts, insisting that investigators be given and
assume adequate responsibility for the conduct of a clinical
trial, have sufficient access to the data to perform the
necessary analyses, and have control over the decision to
publish. The editors further stated that they will “routinely
require authors to disclose details of their own and the
sponsor’s role in the study” and “. . .will ask the responsible
author to sign a statement indicating that he or she accepts
full responsibility for the conduct of the trial, had access to
the data, and controlled the decision to publish” and
“. . .will not review or publish articles based on studies that
are conducted under conditions that allow the sponsor to
have sole control of the data or to withhold publication.”11
Editors may choose not to publish an article if the
sponsor had control over the trial design, data analysis,
and/or publication. These requirements for publication
ethics were adopted as policy on May 11, 2001, and will be
included in the next publication of the “Uniform Require-
ments for Manuscripts Submitted to Biomedical Jour-
nals”—a document to which we are all signatories. The
revised section on “Potential Conflicts of Interest Related
to Project Support” is quoted here.
Increasingly, biomedical studies receive funding from
commercial firms, private foundations, and government. The
conditions of this funding have the potential to bias and
otherwise discredit the research.
Scientists have an ethical obligation to submit creditable
research results for publication. As the persons directly respon-
sible for their work, researchers therefore should not enter into
agreements that interfere with their access to the data or their
ability to analyze the data independently, to prepare manu-
scripts, and to publish them. Authors should describe the role of
the study sponsor(s), if any, in study design; in the collection,
analysis, and interpretation of data; in the writing of the
report; and in the decision to submit the report for publica-
tion. If the supporting source had no such involvement, the
authors should so state. Biases potentially introduced when
sponsors are directly involved in research are analogous to
methodological biases of other sorts; some journals therefore
choose to include information about the sponsor’s involvement
in the methods section of the published paper.
If a study is funded by an agency with a proprietary or
financial interest in the outcome, editors may ask authors to
sign a statement such as, “I had full access to all of the data in
this study and I take complete responsibility for the integrity of
the data and the accuracy of the data analysis.” Editors should
be encouraged to review copies of the protocol and/or contracts
associated with project-specific studies before accepting such
studies for publication. Editors may choose not to consider an
article if a sponsor has asserted control over the authors’ right
to publish.
We, the undersigned surgical journal editors, support
these revised guidelines and, as appropriate, will request
authors of reports on clinical or basic research trials of devices
and drugs to disclose details of the relative roles of the inves-
tigators and the sponsors in the conduct of the trial, the data
collection and analysis, and preparation of the submitted
manuscript. We may also ask the responsible author to sign a
statement that he or she accepts full responsibility for the
conduct of the trial, the validity of the data and its analysis, and
the writing of the submitted manuscript.
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The editors of the Journal of Vascular Surgery strongly endorse the above position paper and the principles that
scientific investigators assume appropriate responsibility for the conduct of industry-sponsored clinical trials, have
sufficient access to the data to perform all necessary analyses, and have control of the decisions relating to when and
where to publish the results.
In January of this year, we modified our policies to reflect this position (“Policy on declaring conditions of funding
for research studies,” 2002;35:197). Further, in last month’s issue, we wrote an editorial on “Protecting the rights
of investigators in industry-supported clinical research” (2002;35:1036-40) suggesting additional broader measures
for dealing with the issues involved. Hopefully, these efforts and a broadening support by both surgical and medical
journal editors will help reaffirm that the primary responsibility for the scientific aspects of industry-supported
research must reside with the principle investigators.
These policies were first approved by the editors of a core group of medical journals (Davidoff F, DeAngelis CD,
Drazen JM, Nicholls MG, Hoey J, Hojgaard L, et al. Sponsorship, authorship, and accountability. N Engl J Med
2001;345:825). We are pleased that we have developed a core group of surgical editors who also support these
policies.
—Robert B. Rutherford, MD, and K. Wayne Johnston, MD
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